DARUNAVIR AND COBICISTAT
Sponsors
Gilead Sciences Inc., Ospedale Pediatrico Bambino Gesu, Shanghai Public Health Clinical Center
Conditions
CoronavirusHIV-1 InfectionPneumonia, Pneumocystisperinatally HIV infection
Phase 3
Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19
NCT04252274
Start: 2020-01-30End: 2020-12-31Target: 30Updated: 2020-04-13
A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care
Active, not recruitingCTIS2024-514047-28-00
Start: 2025-01-27Target: 98Updated: 2025-09-12
The Italian Cohort (ITACO) and the Analytical Antiretroviral Treatment Interruption Italian Cohort (ITACO-ATI) study guided by molecular HIV-1 reservoir profiling
RecruitingCTIS2024-518694-33-00
Start: 2023-08-08Target: 61Updated: 2025-07-24